Literature DB >> 21195741

Tramadol increases extracellular levels of serotonin and noradrenaline as measured by in vivo microdialysis in the ventral hippocampus of freely-moving rats.

P Bloms-Funke1, E Dremencov, T I F H Cremers, T M Tzschentke.   

Abstract

Tramadol is an atypical opioid with monoamine re-uptake inhibition properties. The aim of the current study was to compare, using in vivo microdialysis, the effect of tramadol on extracellular serotonin (5-HT) and noradrenaline (NA) levels in the rat ventral hippocampus with the effects of the dual 5-HT/NA inhibitors (SNRIs) duloxetine and venlafaxine, the tricyclic antidepressant clomipramine, the selective 5-HT re-uptake inhibitor (SSRI) citalopram, and the selective NA re-uptake inhibitor (NRI) reboxetine. It was found that tramadol, duloxetine and venlafaxine increased extracellular levels of both, 5-HT and NA, in a dose-dependent manner. Clomipramine also increased extracellular 5-HT and NA levels, however not dose-dependently in the tested dose range. Citalopram selectively increased extracellular 5-HT levels. Reboxetine increased extracellular NA levels and also to a minimal degree 5-HT levels. It can be concluded that, albeit less efficacious, the effects of tramadol on serotonergic and noradrenergic neurotransmission resemble those of the dual 5-HT and NA re-uptake inhibitors duloxetine, venlafaxine, and clomipramine, and are different from those of the SSRI citalopram and the NRI reboxetine.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21195741     DOI: 10.1016/j.neulet.2010.12.049

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  15 in total

Review 1.  [Serotonin syndrome and pain medication : What is relevant for practice?].

Authors:  M Schenk; S Wirz
Journal:  Schmerz       Date:  2015-04       Impact factor: 1.107

Review 2.  Revisiting Tramadol: A Multi-Modal Agent for Pain Management.

Authors:  Ahmed Barakat
Journal:  CNS Drugs       Date:  2019-05       Impact factor: 5.749

3.  The Effect of Orexin-2 and Endocannabinoid-1 Antagonists on Neuronal Activity of Hippocampal CA1 Pyramidal Neurons in Response to Tramadol in Rats.

Authors:  Vajihe Imanpour; Parham Reisi
Journal:  Adv Biomed Res       Date:  2022-03-30

4.  Mutations in monoamine oxidase (MAO) genes in mice lead to hypersensitivity to serotonin-enhancing drugs: implications for drug side effects in humans.

Authors:  M A Fox; M G Panessiti; P R Moya; T J Tolliver; K Chen; J C Shih; D L Murphy
Journal:  Pharmacogenomics J       Date:  2012-09-11       Impact factor: 3.550

5.  Tramadol and Tramadol+Caffeine Synergism in the Rat Formalin Test Are Mediated by Central Opioid and Serotonergic Mechanisms.

Authors:  Norma Carrillo-Munguía; Ma Eva González-Trujano; Miguel Huerta; Xochitl Trujillo; M Irene Díaz-Reval
Journal:  Biomed Res Int       Date:  2015-06-04       Impact factor: 3.411

6.  Acute and chronic tramadol administration impair spatial memory in rat.

Authors:  Ali Hosseini-Sharifabad; Mohammad Rabbani; Mohammad Sharifzadeh; Narges Bagheri
Journal:  Res Pharm Sci       Date:  2016 Jan-Feb

Review 7.  Review of Post-Marketing Safety Data on Tapentadol, a Centrally Acting Analgesic.

Authors:  Ariane Stollenwerk; Melanie Sohns; Fabian Heisig; Christian Elling; Detlef von Zabern
Journal:  Adv Ther       Date:  2017-12-21       Impact factor: 3.845

8.  EEG and Sleep Effects of Tramadol Suggest Potential Antidepressant Effects with Different Mechanisms of Action.

Authors:  Szabolcs Koncz; Noémi Papp; Noémi Menczelesz; Dóra Pothorszki; György Bagdy
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-04

9.  Biochemical and neurotransmitters changes associated with tramadol in streptozotocin-induced diabetes in rats.

Authors:  Essam Ezzeldin; Wafaa A H Souror; Toqa El-Nahhas; Abdel Nasser M M Soudi; Abdelaaty A Shahat
Journal:  Biomed Res Int       Date:  2014-05-26       Impact factor: 3.411

10.  Opioid-induced inhibition of the human 5-HT and noradrenaline transporters in vitro: link to clinical reports of serotonin syndrome.

Authors:  Anna Rickli; Evangelia Liakoni; Marius C Hoener; Matthias E Liechti
Journal:  Br J Pharmacol       Date:  2018-01-06       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.